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ABSTRACT 
Ruxolitinib is an oral JAK1/JAK2 inhibitor approved for the treatment of patients with myelofibrosis (MF) based 
on the results of two randomized clinical trials. However, discordant indications were provided by regulatory 
agencies and scientific societies for selecting the most appropriate candidates to this drug. The European 
LeukemiaNet and the Italian Society of Hematology shared the aim of building evidence-based 
recommendations for the use of ruxolitinib according to the GRADE methodology. Eighteen patient-
intervention-comparator-outcome  profiles were listed, each of them comparing ruxolitinib to other therapies 
with the aim of improving one of three clinical outcomes: a) splenomegaly, b) disease-related symptoms, and c) 
survival. Ruxolitinib was strongly recommended for improving symptomatic or severe (>15 cm below the costal 
margin) splenomegaly in patients with an IPSS/DIPSS risk INT2 or high. Ruxolitinib was also strongly 
recommended for improving systemic symptoms in patients with a MPN10 score higher than 44, refractory 
severe itching, unintended weight loss not attributable to other causes or unexplained fever. Because of weak 
evidence, the panel does not recommend ruxolitinib therapy for improving survival. Also, the 
recommendations given above do not necessarily apply to patients who are candidates for allogeneic stem cell 
transplant.  
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INTRODUCTION 
In the last  20 years the outcomes of blood cancers in Europe have significantly improved1  proportionally 
to the number of newly approved agents2,3. In 2012 two randomized phase 3 clinical trials reported 
outcomes for myelofibrosis (MF) patients treated with ruxolitinib, a JAK1/JAK2 inhibitor4,5. Ruxolitinib 
therapy was associated with reduction in splenomegaly and improvement of MF-related symptoms and, 
on this basis, it was rapidly approved in the US and EU. Three years later, however, the Cochrane 
Collaboration cast doubts on the real efficacy of this drug since a systematic literature review based on a 
limited follow-up concluded that ruxolitinib did not demonstrate sufficient efficacy for the two principal 
outcomes6. Availability of ruxolitinib in clinical practice, prompted the British Society of Haematology7, 
the European Society of Medical Oncology8 and the Australian Hematology Association9 to elaborate 
recommendations on its use, although they were not based on an explicit GRADE approach.10 As a matter 
of fact, differences between marketing authorization for ruxolitinib and patient selection criteria for the 
COMFORT trials were reckoned as relevant hurdles by the National Institute for Clinical Excellence, which 
finally approved ruxolitinib in 2016 but within strict evidence-based stonemarks. 11 In August 2015, the 
Italian Society of Haematology (SIE) and the European LeukemiaNet (ELN) shared the common effort of 
providing clinicians with strictly evidence-based recommendations for the selection of MF patients 
suitable for Ruxolitinib therapy. This paper reports the process for elaborating such statements according 
to the GRADE methodology and the final recommendations of the expert panel. 
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MATERIALS AND METHODS 
A multi-country panel of 12 senior ELN members with expertise in MF management was convened.  A 
hematologist with expertise in development of clinical practice guideline led the group through the 
following steps, according to the GRADE methodology10: 
1. Listing the three most relevant efficacy outcomes and the two most relevant risk outcomes 
a. Efficacy outcomes: the panel chose splenomegaly, disease-related symptoms and overall 
survival 
b. Risk outcomes: the panel chose bleeding and infection 
2. Listing therapies to be compared with ruxolitinib for the achievement of each specific clinical 
outcome  
a. Comparator therapies were hydroxycarbamide (HU) and interferon (IFN)  
b. Prednisone was also considered a comparator therapy for the outcome “disease-related 
symptoms” 
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3. Formulating an agreed definition for ambiguous terms: 
a. “symptomatic” splenomegaly 
b. “severe” splenomegaly 
c. “relevant” disease-related symptoms 
4. Listing patient-intervention-comparator-outcome (PICO) vignettes (Table 1) 
5. Critical appraisal of available evidence for each of the PICOs 
a. Available evidence was retrieved from the following sources: PubMed, ASH proceedings 
from 2013 ahead and EHA proceedings from 2013 ahead 
b. Evidence was appraised according to the following hierarchy: 
i. Comparative studies with appropriate directness, i.e. control arm corresponding 
to the comparator treatment of the PICO 
ii. Comparative studies without appropriate directness, i.e. control arm does not 
correspond to the comparator treatment of the PICO 
iii. Non-comparative studies 
6. Assessing the net benefit of ruxolitinib versus the comparator treatment in each PICOs 
7. Assessing the quality of evidence according to GRADE, namely based on: 
a. The study design (see hierarchy above) 
b. The study directness, namely the degree of similarity between the study and PICO 
population, intervention and outcome  
8. Scoring 1 to 9 the preference of each panelist for ruxolitinib versus the comparator therapy 
within each PICO 
9. Formulating final recommendations 
10. Assessing the strength of approved recommendations, according to GRADE, namely based on the 
following criteria: 
a. Quality of evidence 
b. Benefit-to-risk balance  
c. Overall uncertainty  
A Delphi panel method12 was used for the steps 1, 2, 3 and 8. Final approval of definitions and 
recommendations was achieved informally during three meetings held in Orlando in December 2015, in 
Mannheim in February 2016, and in Milan in March 2016. 
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RESULTS  
Splenomegaly 
Summary of evidence  
The body of evidence supporting PICOs one to six mainly consisted of the COMFORT II trial, randomizing 
intermediate-2 and high risk MF patients to ruxolitinib or best-available therapy (BAT).4 The clinical 
outcomes of patients assigned to BAT and receiving active treatments (mostly HU) was considered a 
proxy for the clinical outcomes of HU-treated control patients. The COMFORT II trial reported that in 
patients assigned to ruxolitinib spleen volume decreased, on average, by 29% in a median of 12 weeks.4,13 
The probability of maintaining a -35% reduction in spleen volume was 48% at five years, that is a median 
time of response of 3.2 years.13 Rather, palpable spleen size decreased for a few months and by no more 
than 10 cm in a small portion of actively treated patients assigned to BAT: in these patients spleen 
volume increased by 5% in a year.14 The efficacy of ruxolitinib onto spleen size was also supported by the 
randomized trial COMFORT I,5 the prospective study ROBUST15 and the large phase IIIb study JUMP16. A 
definite dose-response was reported.  
Due to the scarce number of IFN-treated patients enrolled into the COMFORT-II control arm, evidence 
from phase II and retrospective studies was sought. One hundred and twenty-six patients reported by 8 
mainly retrospective studies were recently reviewed.17 Spleen response rates reported by the largest 
studies ranged from 30% to 53%, and median time to response was greater than 6 months.17-20 
Finally, we scanned evidence for patients with intermediate-1 risk disease, who were excluded from 
enrollment into the COMFORT trials: phase II15 and phase IIIb16 studies reported a similar efficacy of 
ruxolitinib onto splenomegaly in this subpopulation than in patients with intermediate-2 or high risk 
disease. 
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Quality of evidence  
The overall quality of evidence supporting the net benefit of ruxolitinib in PICOs 1 to 6 was judged to be 
high in principle, due to the randomized design of the COMFORT II trial, but it was necessarily reduced to 
low or very-low due to unblindness and serious indirectness of the study. Serious indirectness was 
caused by a limited portion (47%) of the control arm patients being treated with HU (the comparator 
therapy in PICOs 1 and 2) and by a very small portion of cytoreduction-naive patients (population of 
PICOs 1 to 4). The quality of evidence supporting PICOs 2 to 6 was limited by the very few patients 
receiving interferon in the BAT arm of the COMFORT II trial and by the scarcity of evidence supporting 
interferon efficacy in prospective or comparative studies. However, indirectness was also supported by 
the lack of information regarding spleen size kinetics before enrollment (population of PICOs 2, 4 and 6) 
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and of sub-analyses for patients with symptomatic splenomegaly at enrollment (population of PICOs 1,3 
and 5). The quality of evidence was increased by a clear demonstration of a dose-response relationship 
between ruxolitinib dose and spleen volume reduction.  
Finally, the quality of evidence of ruxolitinib as compared with HU for patients with intermediate-1 risk 
disease was judged to be very low due to the non-randomized design of the studies supporting the safety 
and efficacy of ruxolitinib in this setting. 
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Panel discussion 
The panel agreed that patients with symptomatic and/or severe splenomegaly not responding to prior 
treatment should receive ruxolitinib, based on the rapid and durable reduction of spleen size reported by 
the COMFORT trials.4,5,13 The panel deemed that cytoreduction-naïve patients with symptomatic or 
severe splenomegaly, who also need a rapid and sustained spleen reduction, were expected to get from 
ruxolitinib a similar incremental benefit as pre-treated patients. 
Despite the lack of comparative evidence, the panel also recommended ruxolitinib in a limited subset of 
patients with intermediate-1 risk disease whose quality of life is severely impaired by huge symptomatic 
spleens or splenomegaly-related symptoms not responsive to prior therapies.   
Finally, the panel did not provide any operative definition for “progressive splenomegaly”, however, it 
deemed that treatments aimed at preventing severe or symptomatic splenomegaly might be effectively 
implemented in patients with progressive increase of spleen size, although no evidence from clinical 
trials supports a specific treatment pathway. 
Recommendations 
Although evidence suggests that ruxolitinib is effective in reducing splenomegaly in any patient risk 
category, the benefit/risk profile of the drug favors its use for improving splenomegaly in selected 
patients.  
Ruxolitinib is recommended for improving splenomegaly in: 
– Patients with intermediate-2 or high risk disease and either symptomatic or severe splenomegaly 
(strong recommendation) 
– Patients with intermediate-1 risk disease and either symptomatic or severe splenomegaly not 
responsive or intolerant to HU or interferon (weak recommendation) 
– Patients with intermediate-1 risk disease and both symptomatic and severe splenomegaly not 
previously treated with any cytoreductive agent (weak recommendation) 
“Severe” splenomegaly refers to splenomegaly palpable 15 cm below the costal margin. 
“Symptomatic” splenomegaly refers to the concurrent presence of a splenomegaly and local 
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symptoms not attributable to other causes, such as pain in the left upper quadrant of the 
abdomen, or impairment of food intake due to early satiety. 
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Disease-related symptoms 
Summary of evidence 
Only one study provided direct evidence of ruxolitinib relative efficacy in improving disease-related 
symptoms as compared with other therapies in patients with intermediate-2 or high- risk disease: 
COMFORT II trial reported a similar mean improvement of EORTC Q-C30 score at week 24 in patients 
assigned to ruxolitinib or BAT, provided that the latter were receiving an active treatment.14 Moreover, 
no dose-response relationship was proved by any comparative or non-comparative study. Nevertheless, 
a rapid, relevant and sustained improvement of fatigue, appetite loss and itching was consistently 
reported with ruxolitinib treatment by the COMFORT I and ROBUST trials.5,15 Appetite loss and dyspnea, 
on converse, significantly worsened in BAT-treated patients.14 Despite the universal use of EORTC Q-C30, 
the questionnaire is not disease-specific and includes 30 items, therefore it cannot be feasible outside a 
clinical trial setting. Rather, MPN10 (Table 2) is a brief disease-specific tool applied longitudinally in the 
COMFORT-I trial and validated in several languages, showing a good feasibility. Moreover, MPN10 score 
should be recorded in order to assess response according to IWG-MRT criteria. Despite no “clinically 
meaningful” threshold score for MPN10 has been validated, one third of MF patients enrolled in a cross-
sectional study reported a MPN10 score higher than 44, which can be considered a good cut-off for 
selecting patients with “relevant” disease-related symptoms, in that it corresponds to the mean value 
plus one standard deviation.21  
No study longitudinally assessed quality of life in patients receiving interferon or prednisone. 
Patients with intermediate-1 risk disease enrolled into the ROBUST phase II trial achieved similar 
symptom improvement during ruxolitinib therapy than intermediate-2 and high risk patients.15 
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Quality of evidence 
The overall quality of evidence was judged to be low. Despite the randomized design of the COMFORT II 
trial, several limitations hamper its quality in supporting PICOs 7 to 9: limited size, unblindness, high rate 
of missing data and indirectness add up with lack of a clear-cut improvement in quality of life of patients 
assigned to ruxolitinib as compared with those assigned to active BAT. However, the consistency of the 
data reported by COMFORT II and other studies, namely, COMFORT I and ROBUST, supports a potentially 
relevant effect of ruxolitinib in the patients' quality of life. 
Panel discussion 
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The panel deemed that a systematic and quantitative assessment of MF-associated symptoms with 
MPN10 was feasible and necessary prior to treatment decisions. The panel also considered the 
structured summary of evidence and the poor quality of the evidence supporting a benefit of ruxolitinib 
as compared with BAT, mainly HU. However, the rapid and sustained action of ruxolitinib upon itching, 
appetite and fatigue was considered to be sufficient to strongly recommend it in patients carrying a high 
burden of symptoms, that is to say, with a MPN10 score higher than 44. The panel also deemed that 
ruxolitinib could be recommended for controlling some specific severe symptoms, such as itching, 
relevant weight loss or fever, irrespectively of the overall MPN10 score. The recommendation was 
judged to be valid also in patients with intermediate-1 risk disease, while no exclusion criterion for low-
risk patients was required, since disease-related symptoms are very rare in this setting and would often 
mean that patient risk category is increasing. 
Recommendations 
Accurate assessment by the tools such as MPN10 should be performed before any clinical decision 
regarding the use of ruxolitinib for improving disease-associated symptoms. 
Ruxolitinib is recommended for improving disease-related symptoms in patients with a MPN10 score 
higher than 44 or refractory severe itching (score >6) or unintended weight loss (>10% in the last 6 
months) not attributable to other causes or unexplained fever (Strong recommendation). 
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Survival 
Summary of evidence 
Search for evidence supporting PICOs 10 to 18  could retrieve only one study comparing the survival of 
ruxolitinib-treated patients with the survival of patients assigned to other active treatments. The 
COMFORT II trial reported a significant and relevant increase of five-year survival from 44% (BAT) to 56% 
(ruxolitinib), despite cross-over, in patients with intermediate-2 or high risk disease. Spleen response 
predicted a major improvement of survival.22 A survival benefit in favor of ruxolitinib versus other 
therapies, consisting mainly of HU, was also reported by two case-control studies.23,24  
No evidence compared the overall survival of ruxolitinib-treated with interferon-treated patients. 
No study longitudinally compared the overall survival of intermediate-1 patients receiving ruxolitinib 
rather than other treatments. 
Quality of evidence 
The quality of evidence for PICOs 10 and 11 was judged to be very low despite the randomized design of 
the COMFORT II trial, due to the limited size and lack of blindness of the study but even more due to the 
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severe indirectness provided by the low portion of actively treated patients in the BAT arm. No 
comparative evidence supporting a survival prolongation with ruxolitinib as compared with HU was 
available for patients with intermediate-1 disease (PICO 12). Similarly, no evidence supported a longer 
survival in patients treated with ruxolitinib versus interferon (PICOs 13 to 18). 
Panel discussion 
The panel judges that the universal prescription of a drug should be based on solid evidence supporting 
amelioration of one of the most relevant endpoint, which is survival. The panel, therefore deemed that 
the quality of available evidence for a survival benefit of ruxolitinib versus HU or interferon was not 
sufficient to support a recommendation. 
Recommendations 
The evidence supports a survival benefit associated with ruxolitinib but its quality according to GRADE 
was judged to be very low. Therefore, ruxolitinib should not be recommended uniquely for improving 
survival (weak recommendation). 
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Safety: bleeding and infection  
Comparative safety of ruxolitinib and HU or interferon was available in the COMFORT II trial: 35 out of 
146 (24%) patients assigned to ruxolitinib discontinued the therapy due to adverse events, as compared 
with only 4 out of 73 (5%) patients assigned to BAT.13 Safety outcomes were not judged to 
counterbalance the expected ruxolitinib benefit, however, the panel deemed that the reported safety 
could be reproduced in the clinical practice only  if a proactive prevention of bleeding and infection was 
implemented. 
Bleeding 
Direct evidence of the relative safety of ruxolitinib versus HU was derived only from the COMFORT II 
trial: treatment interruptions due to adverse events were more frequent in patients assigned to 
ruxolitinib (8% versus 3%) as well as grade 3-4 thrombocythopenia (15% versus 5%) and overall bleeding 
events (odds ratio 2.2; 95% CI 1.3-2.7).4,13 Thanks to ruxolitinib dose-adjustment according to baseline 
and follow-up platelet count, severe bleeding was rarely reported (2% to 3%) either in the COMFORT 
trials or in the JUMP study, enrolling almost only patients with baseline platelet count higher than 
100*109/l.4,5,13,16 Severe hemorrhages were also rare (less than 3%) in studies specifically enrolling  
patients with baseline platelet counts 50 to 100*109/l: 5 to 10 mg BID ruxolitinib were administered.25-27  
The reported risk of bleeding related to ruxolitinib-induced thrombocytopenia prompted the panel to list 
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the principal bleeding risk factors: Table 3 lists such factors and the panel recommends a systematic 
assessment of these items before assigning any patient to ruxolitinib therapy. Moreover, the panel 
suggests periodical reassessment of these factors in treated patients. Physicians are advised to ensure 
patient awareness of his/her bleeding risk during the treatment. The panel did not provide any further 
suggestion on starting and continuation dose, which should be titrated based on platelet count, as 
reported by the product information.  
Infection 
The panel listed the most relevant issues to be considered in assessing infection risk (Table 4) and 
deemed that ruxolitinib could not be contraindicated in any specific subset of high-infective risk patients 
but that caution, specific monitoring or prophylactic measures are recommended in patients with at least 
one risk factor. Screening for hepatitis viruses was deemed mandatory in order to implement monitoring 
and/or prevention measures for potentially fatal reactivations. Specific anti-viral or anti-mycobacterial 
preventive measures have been proposed.9,28-29 The panel recommends the infection risk to be 
systematically assessed before administering ruxolitinib and caution in the prescription for patients 
carrying infection risk factors (Table 4). Prophylaxis for patients at high risk of viral or mycobacterial 
infections should be considered on a case to case basis. Moreover, physicians are advised to pursue 
patient awareness of his/her infective risk during the treatment.  
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Special subpopulations  
Due to an overall lack of direct evidence of safety and efficacy, no evidence-based recommendations 
could be elaborated for the following specific subsets of patients. 
Splanchnic vein thrombosis (SVT) and/or portal hypertension 
Myelofibrosis patients with a history of SVT often have splenomegaly and also have a risk of portal 
hypertension with risk of variceal bleeding. They were identified as a special subpopulation. The panel 
elaborated safety recommendations based on eligibility criteria of a small phase II trial enrolling 21 
patients with myeloproliferative neoplasms (including 12 MF) actively treated with anticoagulants or 
antiplatelet drugs and both showing a platelet count higher than 100*109/l at baseline and esophageal 
varices of grade 2 or lower.30 Ruxolitinib was administered at reduced doses for patients with a baseline 
platelet count lower than 200*109/l: 10 mg BID for PV, 15 mg BID for MF and 25 mg BID for ET. Despite 
the occurrence of grade 3-4 thrombocytopenia in 14.3% of the patients, accurate dose reductions limited 
bleeding events and only one episode of grade 2 upper gastrointestinal bleeding occurred during the 
study period. However, the reported background rate of major hemorrhage in this setting is quite low, 
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i.e. 3.6/100 patient-years.31,32 However, due to the large unmet needs of this patient subpopulation, the 
panel deemed not to recommend against ruxolitinib in this setting, but to use ruxolitinib with caution 
and to carefully titrate the dose with careful monitoring and management of portal hypertension. If 
ruxolitinib is used in these patients, patient awareness of bleeding risk is required. 
Hepatomegaly 
Some splenectomized patients have been reported as achieving a reduction of hepatomegaly during 
ruxolitinib treatment.33,34 The panel could not provide specific recommendations in favor or against the 
use of ruxolitinib in this subset of patients. However, the panel agreed that ruxolitinib can be considered 
in this clinical situation.  
Comorbidities and limited-lifespan 
The use of ruxolitinib was also questioned in patients with severe comorbidities which are expected to 
limit lifespan by themselves. Only a few patients aged over 80 years were enrolled into randomized 
COMFORT trials and the JUMP studies.4,5,16 Moreover, only 13% and 8% of patients assigned to ruxolitinib 
and BAT, respectively, showed a performance score ECOG 2 or higher.4 Comorbidities were not 
systematically reported by the COMFORT and the JUMP studies, but half of MF patients have a significant 
comorbidity burden in routine care.35 No evidence of a clear benefit-to-risk ratio of ruxolitinib as 
compared with other available treatments has been reported in patients with limited lifespan or severe 
comorbidities. Therefore, the panel recommended avoidance of this drug in such patients, until 
favorable evidence is available. 
Low-risk disease 
The panel could not formulate any specific recommendation for the use of ruxolitinib in patients with 
low risk disease, due to insufficient evidence.  
 
272 
273 
274 
275 
276 
277 
278 
279 
280 
DISCUSSION 
Ruxolitinib represents a novel therapeutic opportunity for patients with MF. However conflicting 
indications to its use in the clinical practice have been provided, some being based on disease risk and 
others on symptoms.7-9,36,37 In comparison with other published statements, the ELN-SIE panel chose to 
adopt the GRADE methodology to formulate evidence-based recommendation for an appropriate use of 
ruxolitinib. Evidence was retrieved and appraised for 18 PICOs (Table 1) and the panel subsequently 
formulated recommendations based on the benefit-to-risk profile of ruxolitinib, as compared with other 
available treatments. Six evidence-based recommendations were therefore formulated suggesting to use 
ruxolitinib for improving symptomatic or severe splenomegaly in patients with intermediate or high risk 
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disease not responsive to cytoreductive agents. Ruxolitinib was also strongly recommended in patients 
with relevant disease-associated symptoms, provided that symptoms were adequately quantified and 
classified. Therefore, a strong suggestion to ruxolitinib use was formulated only for patients scoring over 
44 points by the MPN10; or suffering severe itching not responsive to standard therapy, or with either 
unexplained fever or unintended weight loss. Due to the urgent need for treatment, despite the scarce 
evidence, ruxolitinib was also recommended upfront for those patients with INT1 risk disease suffering 
from both symptomatic and severe splenomegaly. The panel, however, chose not to recommend 
ruxolitinib uniquely aimed at survival prolongation since no study has been designed and powered 
sufficiently to provide  definite evidence. This finally suggests to target therapeutic decisions on 
symptoms and splenomegaly and not on survival. Such recommendations, however, also need to be 
timely revised according to newly coming evidence.    
ELN-SIE recommendations differ from those provided by the British Committee for Standards in 
Hematology7 and by ESMO8. Both suggested ruxolitinib for patients with symptomatic splenomegaly or 
constitutional symptoms but did not provide the physician with a detailed support for interpreting the 
intensity and specificity of symptoms. ELN-SIE also struggled with using a  solid methodology for 
evidence appraisal. The whole decision process was tracked and summarized in the paper, in order to get 
the best transparency and to provide the best evidence-to-recommendation adherence.  
Despite the rigid GRADE methodology imposes a comparison between intervention and comparator 
treatments, the huge and rapid improvement of symptoms reported during ruxolitinib treatment led the 
panel to provide recommendations despite the scarce availability or poor quality of comparative 
evidence. Rather, a strict comparison-based high quality evidence was requested by the panel for 
considering ruxolitinib with the unique aim of improving survival. Therefore, the major result of this 
project was a definite distinction between the enrollment criteria of the registration trials and the 
decisional criteria for ruxolitinib prescription in clinical practice. Moreover, systematic and stringent 
definitions of “relevant” symptoms or splenomegaly were provided, favoring a homogenous and non-
subjective assignment of the most suitable patients to ruxolitinib.  
Some issues were not addressed, however, by the present project, such as the rules for treatment 
discontinuation. IWG-MRT and ELN classified as “responsive” those patients achieving a 50% reduction of 
disease-related symptoms as assessed with MPN10 or a 50% reduction of spleen size from left costal 
margin.38 A list of practical issues are faced in assessing the clinical response to ruxolitinib, such as 
appropriate timing of response assessment in patients receiving full dose or suboptimal doses.39 The 
panel chose not to provide specific recommendations on the modality and timing of response 
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assessment or drug tapering before interruption. However, this was considered to be a relevant issue. 
Furthermore, we did not include recommendations for ruxolitinib in patients who are candidates for 
allogeneic SCT, since an EBMT/ELN consensus conference recently provided specific indications on 
transplantation and peri-transplant therapies.40 To be definitive on the role of ruxolitinib as bridge to 
transplant, we decided to wait results from ongoing prospective trials. However, we have to mention 
that the vast majority of patients with indications to allogeneic SCT are on ruxolitinib treatment. Nor 
does this paper address combination therapies including ruxolitinib, since only preliminary data are 
available from phase 1/2 studies.  Finally, decision models estimated that ruxolitinib might reduce 
disease-related costs in responders, but the overall value-for-cost of the drugs has not been completely 
ascertained yet.42-43 Therefore, the present recommendations did not consider cost among the relevant 
GRADE outcomes.  However, the panel deemed that an appropriate clinical use of ruxolitinib should 
assure a favorable value-for-cost. 
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